Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.

Journal article

INTRODUCTION: The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. Disease incidence is low in healthy 6 - 17-year-old children and young people; however, there are a number of clinical conditions that put individuals in this age group at increased risk. Expansion of the license of a 13-valent pneumococcal conjugate vaccine , PCV-13, to include the 6 - 17 age group has recently been approved by European and American regulatory bodies. AREAS COVERED: Studies assessing the safety, immunogenicity, and efficacy of pneumococcal conjugate vaccines in both healthy and high-risk 6 - 17-year-old children and adolescents are covered and the potential impact of PCV-13 in these populations is discussed. The use of the 23-valent pneumococcal polysaccharide vaccine, PPV-23, in high-risk children and adolescents is also considered. EXPERT OPINION: Expanding the use of PCV-13 to include high-risk children and adolescents aged 6 - 17 has the potential to prevent additional cases of disease; however, vaccination of this population may no longer be necessary when herd immunity to PCV-13 serotypes becomes fully established. Despite the broader serotype coverage of PPV-23, the benefits of this vaccine in high-risk populations are uncertain.

Authors: Mitchell, R; Trück, J; Pollard, A

• Publication status: Published
• Journal: Expert opinion on biological therapy
• Volume: 13
• Issue: 10
• Pages: 1451-1465
• Publication date: 2013-10-01
• DOI: 10.1517/14712598.2013.824419
• EISSN: 1744-7682
• ISSN: 1471-2598
• Language: English
• Keywords: Vaccination; Adolescent; Child; Immunization Schedule; Humans; Vaccines, Conjugate; Pneumococcal Vaccines; Streptococcus pneumoniae; Pneumococcal Infections